The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 06, 2025

Filed:

Apr. 28, 2021
Applicants:

Inje University Industry-academic Cooperation Foundation, Gimhae-si, KR;

Seoul National University Hospital, Seoul, KR;

Inventors:

Jae Seung Chung, Busan, KR;

Ki-Ho Han, Busan, KR;

Hyung Seok Cho, Busan, KR;

Jae Il Chung, Busan, KR;

Seok-Soo Byun, Seongnam-si, KR;

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
G01N 33/574 (2005.12); A61K 31/337 (2005.12); A61P 35/00 (2005.12); C12Q 1/00 (2005.12); C12Q 1/68 (2017.12); C12Q 1/6886 (2017.12); G01N 33/00 (2005.12); G01N 33/50 (2005.12); G01N 33/543 (2005.12);
U.S. Cl.
CPC ...
G01N 33/57492 (2012.12); G01N 33/57434 (2012.12); A61K 31/337 (2012.12); A61P 35/00 (2017.12); C12Q 1/6886 (2012.12); C12Q 2600/118 (2012.12); C12Q 2600/158 (2012.12); G01N 33/54326 (2012.12); G01N 2333/4742 (2012.12); G01N 2333/705 (2012.12); G01N 2333/70596 (2012.12); G01N 2333/723 (2012.12);
Abstract

The present invention relates to a biomarker composition for diagnosing and predicting prognosis of prostate cancer, and that the detection rate and expression level of gene combination composed with AR (Androgen receptor), AR-V7 (Androgen receptor variant 7), EpCAM (Epithelial cell adhesion molecule) in blood tumor cells (CTC) isolated from patients, Epithelial cell adhesion molecule), KRT-19 (Cytokeratin 19), PSA (Prostate specific antigen), and PSMA (Prostate specific membrane antigen) in circulating tumor cells (CTCs) isolated from patients is related to the level of malignancy in prostate cancer is confirmed and thus the gene combination provides as a biomarker for prostate cancer diagnosis and a biomarker for prognosis prediction of prostate cancer.


Find Patent Forward Citations

Loading…